Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): Design of a prospective randomized multicenter trial

Journal of Nephrology

Volumn 14, Issue 1, 2001, Pages 15-18

  Boero, R ^a   Rollino, C ^a   Massara, C ^a   Vagelli, G ^a   Gonella, M ^a   Berto, I M ^a   Bajardi, P ^a   Perosa, P ^a   Malcangi, U ^a   Giorgi, M P ^a   Ghezzi, P M ^a   Borzumati, M ^a   Baroni, A M ^a   Cogno, C ^a   Triolo, G ^a   Angelini, D ^a   Antonelli, A ^a   Quarello, F ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Angiotensin converting enzyme inhibitors; Calcium channel blockers; Nephropathies; Proteinuria; Randomised trials

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CREATININE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; PLACEBO; TRANDOLAPRIL; VERAPAMIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIET RESTRICTION; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; PROTEIN TRANSPORT; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; KIDNEY DISEASES; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RESEARCH DESIGN; VERAPAMIL;

EID: 0035097024     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies
2. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study
3. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency
4. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
5. Short term antiproteinuric response to antihypertensive treatment predicts long term GFR decline in patients with non-diabetic renal disease
6. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment
7. Why is proteinuria such an important risk factor for progression in clinical trials?
8. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic disease: A meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group
9. The sixth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC-VI)
10. Effects of dihydropiridine calcium channel blockers, angiotensin converting enzyme inhibition, and blood pressure control on chronic non-diabetic nephropathies
11. Antihypertensive treatment of patients with proteinuric renal diseases: Risk or benefits of calcium channel blockers?
12. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus
13. Treatment of arterial hypertension in diabetic man: Importance of therapeutic selection
14. Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease
15. Il metodo della ricerca clinica. Dimensioni del campione